A correlação entre o vírus da imunodeficiência humana e demência na terceira idade / The correlation between the human immunodeficiency virus and dementia in old age

Geovana Braz Nascimento, Marco Túlio Batista Vaz Filho, Ayla Solano Marques, Alexandre Rodrigues Ferreira de Oliveira, Lo-ruama Porto Viana, Isabelly Sousa Dias, Ester de Oliveira Teixeira, Maria Flávia Campos Adelino, Lucas Buozi Gonçalves Girotti, Matheus Henrique Santos Cardoso, Hellen Rodrigues Teixeira Silva Daameche

Abstract


Introdução: A demência causa processos neurodegenerativos graduais e, quando associada a replicação sistêmica do Vírus da Imunodeficiência Humana (HIV), predispõe um pior prognóstico devido à produção de déficits maiores na memória verbal. Objetivos: analisar as informações sobre a correlação entre o HIV e a demência na terceira idade, elucidando os aspectos fisiopatológicos e clínicos da doença. Metodologia: A revisão bibliográfica, de estudos publicados nos últimos 5 anos, utilizou como descritores “Demência” e “HIV’’, para então integrar os estudos dos indexadores MEDLINE e LILACS. Posteriormente, um artigo indexado no Google Scholar foi adicionado para complementação da literatura. Resultados: Vinte e quatro estudos foram selecionados, dos quais 20 estão indexados na base de dados da MEDLINE, três no LILACS e um no Google Scholar, sendo que dentre os artigos escolhidos seis foram revisões bibliográficas, seis estudos de Coorte, seis ensaios clínicos, dois estudos observacionais, dois estudos de rastreamento e dois retrospectivos. Conclusão: Concluiu-se que o sistema nervoso central é o principal alvo das disfunções neurocognitivas associadas ao HIV, com avaliação clínica de difícil execução e possuindo como terapia mais indicada para tratamento a terapia antiretroviral combinada devido sua capacidade de diminuição da carga viral no organismo do paciente infectado.


Keywords


Demência, HIV, Idoso.

References


ANDERSON, Albert M. et al. Plasma and cerebrospinal fluid biomarkers predict cerebral injury in HIV-infected individuals on stable combination antiretroviral therapy. Journal of acquired immune deficiency syndromes (1999), v. 69, n. 1, p. 29, 2015.

BRITO-MARQUES, Paulo Roberto et al. Comparison between the Mini-Mental State Examination and Montreal Cognitive Assessment as a Cognitive Screening Tool in Patients with Human Immunodeficiency Virus-Associated Neurocognitive Disorders. Revista da Sociedade Brasileira de Medicina Tropical, v. 52, 2019.

BROUILLETTE, Marie-Josée et al. Identifying neurocognitive decline at 36 months among HIV-positive participants in the CHARTER Cohort using group-based trajectory analysis. PloS one, v. 11, n. 5, p. e0155766, 2016.

CARVALHAL, Adriana et al. Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study. Journal of neurovirology, v. 22, n. 3, p. 349-357, 2016.

CHOW, Felicia C. et al. Cerebral Vasoreactivity Evaluated by the Breath-Holding Challenge Correlates With Performance on a Cognitive Screening Test in Persons Living With Treated HIV Infection in China. JAIDS Journal of Acquired Immune Deficiency Syndromes, v. 79, n. 3, p. e101-e104, 2018.

CHRISTO, Paulo Pereira. Alterações cognitivas na infecção pelo HIV e Aids. Rev. Assoc. Med. Bras. 2010, vol.56, n.2, pp.242-247.

COBAN, Hamza et al. Impact of aging on neurocognitive performance in previously antiretroviral-naïve HIV+ individuals on their first suppressive regimen. AIDS (London, England), v. 31, n. 11, p. 1565, 2017.

EGGERS, Christian et al. HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment. Journal of neurology, v. 264, n. 8, p. 1715-1727, 2017.

FERNÁNDEZ-CRUZ, Ana Lucia; FELLOWS, Lesley K. The electrophysiology of neuroHIV: a systematic review of EEG and MEG studies in people with HIV infection since the advent of highly-active antiretroviral therapy. Clinical Neurophysiology, v. 128, n. 6, p. 965-976, 2017.

FIELDS, Jerel Adam et al. Alterations in brain TREM 2 and Amyloid‐β levels are associated with neurocognitive impairment in HIV‐infected persons on antiretroviral therapy. Journal of neurochemistry, v. 147, n. 6, p. 784-802, 2018.

FOGEL, J. et al. Effects of sex and HIV serostatus on spatial navigational learning and memory among cocaine users. Journal of neurovirology, v. 23, n. 6, p. 855-863, 2017.

FREITAS, E. V. D.; PY, L. Tratado de Geriatria e Gerontologia. 4. ed. Rio de Janeiro: Guanabara koogan, 2017.

GATES, Thomas M. et al. Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder. Aids, v. 30, n. 4, p. 591-600, 2016.

GHATE, Manisha et al. The effects of antiretroviral treatment initiation on cognition in HIV-infected individuals with advanced disease in Pune, India. Journal of neurovirology, v. 21, n. 4, p. 391-398, 2015.

ISRAEL, Sarah M. et al. Different roles of frontal versus striatal atrophy in HIV‐associated neurocognitive disorders. Human brain mapping, v. 40, n. 10, p. 3010-3026, 2019.

JOSKA, J. A. et al. A comparison of five brief screening tools for HIV-associated neurocognitive disorders in the USA and South Africa. AIDS and Behavior, v. 20, n. 8, p. 1621-1631, 2016.

KAMI-ONAGA, Kaoru et al. Comparison of two screening tests for HIV-Associated Neurocognitive Disorder suspected Japanese patients with respect to cART usage. PloS one, v. 13, n. 6, p. e0199106, 2018.

KAMMINGA, Jody et al. Monitoring HIV-associated neurocognitive disorder using screenings: a critical review including guidelines for clinical and research use. Current Hiv/aids Reports, v. 14, n. 3, p. 83-92, 2017.

KIM, Woo Jung et al. Utility of the Montreal Cognitive Assessment (MoCA) and its subset in HIV-associated neurocognitive disorder (HAND) screening. Journal of psychosomatic research, v. 80, p. 53-57, 2016.

MARIN-WEBB, Victor et al. Validation of the international HIV dementia scale as a screening tool for HIV-associated neurocognitive disorders in a German-speaking HIV outpatient clinic. PloS one, v. 11, n. 12, p. e0168225, 2016.

MOLINARO, Maria et al. Utility of the International HIV Dementia Scale for HIV-Associated Neurocognitive Disorder. JAIDS Journal of Acquired Immune Deficiency Syndromes, v. 83, n. 3, p. 278-283, 2020.

MOLSBERRY, Samantha A. et al. Neuropsychological phenotypes among men with and without HIV disease in the multicenter AIDS cohort study. AIDS (London, England), v. 32, n. 12, p. 1679, 2018.

MONROE, A. K. et al. The association between physical activity and cognition in men with and without HIV infection. HIV medicine, v. 18, n. 8, p. 555-563, 2017.

NDHLOVU, Lishomwa C. et al. Loss of CCR2 expressing non-classical monocytes are associated with cognitive impairment in antiretroviral therapy-naive HIV-infected Thais. Journal of neuroimmunology, v. 288, p. 25-33, 2015.

PARRY, Sarah et al. Simple screening for neurocognitive impairment in routine HIV outpatient care: is it deliverable?. AIDS care, v. 29, n. 10, p. 1275-1279, 2017.

PORTO, Celmo Celeno. Semiologia médica; coeditor Arnaldo Lemos Porto. - 8. ed. - Rio de Janeiro: Guanabara Koogan, 2019.

PEREIRA, Saulo Freitas et al. Relação entre os exercícios aeróbios e qualidade de vida de pessoas que vivem com HIV/AIDS/Relation between aerobic exercises and quality of life of people living with HIV/AIDS. Brazilian Journal of Health Review, v. 1, n. 2, p. 439-446, 2018.

RUBIN, Leah H. et al. A single low-dose of hydrocortisone enhances cognitive functioning in HIV-infected women. AIDS (London, England), v. 32, n. 14, p. 1983, 2018.

SOUZA, Elisa Moreira de et al. Risk factors for neurocognitive impairment in HIV-infected patients and comparison of different screening tools. Dementia & Neuropsychologia, v. 10, n. 1, p. 42-46, 2016.

TSAI, Yi-Tseng et al. Incidence of neurological disorders among HIV-infected individuals with universal health care in Taiwan from 2000 to 2010. JAIDS Journal of Acquired Immune Deficiency Syndromes, v. 75, n. 5, p. 509-516, 2017.

UNDERWOOD, Jonathan et al. Medicalising normality? Using a simulated dataset to assess the performance of different diagnostic criteria of HIV-associated cognitive impairment. PloS one, v. 13, n. 4, p. e0194760, 2018.

WINSTON, Alan et al. Changes in cognitive function over 96 weeks in naive patients randomized to darunavir–ritonavir plus either raltegravir or tenofovir–emtricitabine: a substudy of the NEAT001/ANRS143 trial. JAIDS Journal of Acquired Immune Deficiency Syndromes, v. 74, n. 2, p. 185-192, 2017.




DOI: https://doi.org/10.34119/bjhrv4n1-178

Refbacks

  • There are currently no refbacks.